Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06064084
Other study ID # 11031999
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 11, 2011
Est. completion date September 11, 2015

Study information

Verified date September 2023
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date September 11, 2015
Est. primary completion date September 11, 2015
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls) Exclusion Criteria: other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Oral glucose tolerance test
Oral glucose tolerance test 50g
Other:
Intravenous isoglycaemic glucose clamp
Intravenous isoglycaemic glucose clamp
Liquid Mixed meal test
Liquid Mixed meal test 520 kcal

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Gentofte, Copenhagen

Outcome

Type Measure Description Time frame Safety issue
Primary Incretin effect measured with Beta-cell secretory response Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT) 0-180 minutes
Secondary Insulin sensitivity measures Matsudas insulin sensitivity index: (10,000 / vglucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT)) 0-180 minutes
Secondary Concentration of Glucose-independent insulinotropic polypeptide Evaluted as Area Under the Curve 0-180 minutes
Secondary Concentration of Glucagon-like peptide 1 Evaluated as Area Under the Curve 0-180 minuntes
Secondary Concentration of Glucagon Evaluated as Area Under the Curve 0-180 minutes
Secondary Concentration of Insulin Evaluated as Area Under the Curve 0-180 minutes
See also
  Status Clinical Trial Phase
Completed NCT03669757 - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis Phase 1
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Completed NCT03584360 - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin Phase 2
Recruiting NCT04994951 - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome. Phase 2
Completed NCT02888236 - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris Phase 2
Completed NCT02533973 - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Phase 4
Completed NCT02193815 - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis Phase 1
Completed NCT02004847 - Blue Light for Treating Psoriasis Vulgaris N/A
Completed NCT01946386 - A Vasoconstriction Study With LEO 90100 Phase 1
Recruiting NCT01443338 - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Phase 4
Completed NCT01188928 - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) Phase 3
Completed NCT00764751 - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris Phase 2
Completed NCT00236171 - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test N/A
Completed NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade Phase 4
Not yet recruiting NCT06398106 - Proactive TDM Versus Standard Use of Biologics in Psoriasis Phase 4
Recruiting NCT05390515 - Psoriatic Immune Response to Tildrakizumab Phase 4
Recruiting NCT05892640 - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT05184348 - Plexin B2 Gene Expression and Polymorphisms in Psoriasis Phase 1
Recruiting NCT04394936 - An Explorative Psoriasis Biomarker Study N/A